Sorin Hopes Improving CRT Response Rate Will Lead To Growth In U.S. Market
This article was originally published in The Gray Sheet
Executive Summary
The Italian company is set to launch the RESPOND CRT trial of its SonR cardiac resynchronization therapy, which Sorin expects will be an important differentiator that allows the company to compete more aggressively in the U.S. market.